Genprex grants 28,500 RSUs to Chief Medical Officer
Genprex, Inc. reported that its Chief Medical Officer received an award of 28,500 restricted stock units (RSUs) of common stock on 12/22/2025.
Rhea-AI Filing Summary
Genprex, Inc. reported that its Chief Medical Officer received an award of 28,500 restricted stock units (RSUs) of common stock on 12/22/2025. The RSUs were granted at a price of $0 per share under the company’s 2018 Equity Incentive Plan, as amended and restated effective June 30, 2025.
The award vests in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, conditioned on continued service through each vesting date. Once vested, each RSU will be settled in one share of Genprex common stock. After this grant and giving effect to a 1-for-50 reverse stock split of Genprex’s common stock that was effective as of October 21, 2025, the reporting officer beneficially owns 28,860 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 28,500 | $0.00 | $0.00 |
Footnotes (2)
- F1. This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.
- F2. This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.